MNKD - マンカインド (MannKind Corporation) マンカインド

 MNKDのチャート


 MNKDの企業情報

symbol MNKD
会社名 MannKind Corp (マンカインド)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 マンカインド(MannKind Corporation)は開発段階の生物薬剤学企業であり、糖尿病と癌など疾患用の治療薬の発見・開発・商業化に集中する。同社の製品候補AFREZZA(ヒトインスリン)吸入パウダーは、血糖コントロールのための1型や2型糖尿病を患う成人向けの治療用の後期臨床研究段階にあるインスリン。AFREZZA吸入パウダーは、酸性・塩基性度(pH) 感知の有機分子クラスに集中する。AFREZZAはテクノスフィア処方設計技術を利用する。平成23年12月31日現在、同社の製品より収入はない。平成23年12月31日現在、AFREZZA臨床プログラムは、61の異なるAFREZZA研究及び5600以上の成人患者を含まれている。   マンカインドは米国のバイオ医薬品メ―カ―。主に糖尿病疾患の治療薬の発見・開発・製品化に従事。製品候補のAFREZZA(ヒトインスリン)吸入粉末は、I型またはII型糖尿病成人における血糖コントロ―ルを改善する可能性がある。AFREZZAはテクノスフィア製剤技術を利用している。本社はカリフォルニア州。   MannKind Corp. is a biopharmaceutical company. It focuses on the discovery, development and, commercialization of therapeutic products for diseases, such as diabetes and cancer. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Westlake Village, CA.
本社所在地 25134 Rye Canyon Loop Suite 300 Valencia CA 91355 USA
代表者氏名 Kent Kresa ケント・クレッサ
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 818-661-5000
設立年月日 33270
市場名 NASDAQ National Market System
ipoyear 2004年
従業員数 192人
url www.mannkindcorp.com
nasdaq_url https://www.nasdaq.com/symbol/mnkd
adr_tso
EBITDA EBITDA(百万ドル) -98.39600
終値(lastsale) 1.71
時価総額(marketcap) 271441752.57
時価総額 時価総額(百万ドル) 304.44680
売上高 売上高(百万ドル) 13.93100
企業価値(EV) 企業価値(EV)(百万ドル) 407.62780
当期純利益 当期純利益(百万ドル) -118.73000
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 MannKind Corporation revenues increased 42% to $7.4M. Net loss increased 3% to $53.1M. Revenues reflect Net revenue - commercial product sales increase from $2.7M to $7.2M Net revenue - collaboration increase of 19% to $150K. Higher net loss reflects General and Administrative increase of 25% to $42.3M (expense) Interest Exp-Net of Capitalized Interest increase of 51% to $2.2M (expense).

 MNKDのテクニカル分析


 MNKDのニュース

   MannKind Is Crushing It, but Beware or You'll Be Crushed  2020/06/24 14:05:27 InvestorPlace
Before you consider going all in on MNKD stock, consider that the company is itself going all in on one product, and that comes with risks.
   The Daily Biotech Pulse: MediciNova On Track For European Patent Win, Partial Clinical Hold Lifted For Innate Pharma, Tela Bio Details Coronavirus Impact  2020/06/24 12:07:18 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 23) ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD ) Acceleron Pharma Inc (NASDAQ: XLRN ) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) Avidity Biosciences Inc (NASDAQ: RNA ) (went public June 12) BioXcel Therapeutics Inc (NASDAQ: BTAI ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (went public June 12) Corcept Therapeutics Incorporated (NASDAQ: CORT ) Crispr Therapeutics AG (NASDAQ: CRSP ) (moved on analyst action) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Dyadic International, Inc. (NASDAQ: DYAI ) Editas Medicine Inc (NASDAQ: EDIT ) GENMAB A/S/S ADR (NASDAQ: GMAB ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ) Hologic, Inc. (NASDAQ: HOLX ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Immunomedics, Inc.
   The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout  2020/06/23 11:57:59 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.
   Implied Volatility Surging for MannKind (MNKD) Stock Options  2020/06/18 12:49:12 Yahoo Finance
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
   MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference  2020/06/17 21:00:00 GlobeNewswire
WESTLAKE VILLAGE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual…
   The Daily Biotech Pulse: Sanofi Expedites COVID-19 Vaccine Timeline, Apyx Cleared For Market Expansion, Miragen's Positive Readout  2020/06/23 11:57:59 Benzinga
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) ADC Therapeutics SA (NYSE: ADCT ) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Aeglea Bio Therapeutics Inc (NASDAQ: AGLE ) Affimed NV (NASDAQ: AFMD ) - announced presentation at the AACR Virtual Meeting II, data on the Bristol-Myers Squibb Co (NYSE: BMY ) unit Genentech's RO7297089 and AFM24 developed from Affimed's ROCK platform Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY ) Amicus Therapeutics, Inc. (NASDAQ: FOLD ) Ascendis Pharma A/S (NASDAQ: ASND ) (presented at the AACR Virtual Meeting II with pre-clinical data for oncology product candidate) Atossa Therapeutics Inc (NASDAQ: ATOS ) Burning Rock Biotech Ltd (NASDAQ: BNR ) (announced full exercise of over-allotment option in IPO) Cytokinetics, Inc. (NASDAQ: CYTK ) Dyadic International, Inc. (NASDAQ: DYAI ) Evoke Pharma Inc (NASDAQ: EVOK ) ( announced FDA approval for inhaled formulation of its gastroparesis drug) Five Prime Therapeutics Inc (NASDAQ: FPRX ) (moved higher on an analyst upgrade) GENMAB A/S/S ADR (NASDAQ: GMAB ) GenMark Diagnostics, Inc (NASDAQ: GNMK ) Halozyme Therapeutics, Inc.
   Implied Volatility Surging for MannKind (MNKD) Stock Options  2020/06/18 12:49:12 Yahoo Finance
Investors need to pay close attention to MannKind (MNKD) stock based on the movements in the options market lately.
   MannKind Corporation to Present at the June 2020 Lytham Partners Virtual Investor Growth Conference  2020/06/17 21:00:00 GlobeNewswire
WESTLAKE VILLAGE, Calif., June 17, 2020 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) announced today that it will be featured in a virtual…
   MannKind (MNKD) Stock Could Nearly Double in the Next Year, Says Analyst  2020/05/20 00:44:43 Smarter Analyst
It has been a rough five years for investors of diabetes-focused biotech MannKind (MNKD). Over the period, shares of the company have declined … The post MannKind (MNKD) Stock Could Nearly Double in the Next Year, Says Analyst appeared first on Smarter Analyst .
   MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates  2020/05/06 21:15:04 Zacks Investment Research
MannKind (MNKD) delivered earnings and revenue surprises of 50.00% and 7.16%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
   MannKind Q4 Afrezza sales up 37%; shares ahead 3% premarket  2020/02/25 13:14:19 Seeking Alpha
MannKind (MNKD) Q4 results: Revenues: $16M (-0.2%); Afrezza net revenue: $7.8M (+36.8%); Collaborations/services: $8.2M (-21.2%). Net loss: ($14.3M) (-45.9
   MannKind Corporation (MNKD): Q4 2019 Earnings Snapshot  2020/02/25 13:10:59 news.alphastreet.com
— MannKind Corporation (NASDAQ: MNKD) reported Q4 2019 loss of $0.07 per share, vs. a loss of $0.07 expected. — Total revenue amounted to $16…
   MannKind (NASDAQ: MNKD): Q3 2019 Earnings Snapshot  2019/11/06 13:38:37 news.alphastreet.com
— MannKind Corporation (NASDAQ: MNKD) reported a third-quarter 2019 loss of $0.05 per share versus a loss of $0.08 per share expected. — The results…
   MannKind Receives Second $12.5 Million Milestone Payment From United Therapeutics  2019/11/04 14:00:00 ACI Information Group
WESTLAKE VILLAGE, Calif., Nov. 04, 2019 -- MannKind Corporation (NASDAQ: MNKD) today announced that it has achieved the second of four specified development milestones under.
   Dry Powder Inhaler Market Getting High Rise Due To Growing Adoption of Unhealthy Lifestyle – Study 2017-2024 by Key Players Like Mannkind Corporation, Cipla Inc. and Others  2019/08/13 13:41:00 MarketWatch
Aug 13, 2019 (AmericaNewsHour) -- Dry powder inhaler is referred to a device that helps to deliver medication to the lungs in the form of dry powder. Dry…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 マンカインド MNKD MannKind Corporation)

 twitter  (公式ツイッターやCEOツイッターなど)